BANK VONTOBEL/CALL/BIOGEN IDEC/310/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 13:53:52 2024-07-04 EDT | ||
| 0.044 EUR | +2.33% |
|
| Current month | -32.31% | ||
| 1 month | -77.78% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-04 | 0.044 | +2.33% |
| 24-07-03 | 0.043 | -36.76% |
| 24-07-02 | 0.068 | -28.42% |
| 24-07-01 | 0.095 | +46.15% |
| 24-06-28 | 0.065 | +75.68% |
Delayed Quote Deutsche Boerse AG
Last update July 04, 2024 at 01:53 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VM36A1 |
| ISIN | DE000VM36A15 |
| Date issued | 2023-10-18 |
| Strike | 310 $ |
| Maturity | 2024-09-20 (78 Days) |
| Parity | 10 : 1 |
| Emission price | 2.21 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.49 € |
|---|---|
| Lowest since issue | 0.007 € |
| Spread | 0.021 € |
| Spread % | 32.31% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
224.6
USD
Average target price
283.2
USD
Spread / Average Target
+26.06%
- Stock Market
- Warrants
- Warrant
